General vaccine surveillance

Tracking health events after vaccination: latest results from CANVAS-COVID

The CANVAS-COVID study, funded by the CITF/Vaccine Surveillance Reference Group (VSRG), has collected self-reported information on health events following vaccination in more than one million Canadians so far. The core findings indicate that the incidence of serious side effects, emergency room visits, and hospitalizations following COVID-19 vaccination remain exceedingly rare. Results from the CANVAS-COVID study [...]

2021-09-20T22:27:56-04:00September 21, 2021|General vaccine surveillance|

Poor antibody response to the first dose of the Pfizer-BioNTech vaccine for patients with chronic kidney disease

Patients with chronic kidney disease, including those on dialysis, have been prioritized for vaccination due to increased risk of severe COVID-19 outcomes such as hospitalization and death. In a CITF-funded study now published in JAMA Network Open, several CITF and VSRG-affiliated researchers, including Drs. Michelle Hladunewich and Matthew Oliver report that many dialysis patients [...]

2021-09-16T09:20:28-04:00September 14, 2021|General vaccine surveillance|

Survey offers new insight into which Canadians do not intend to get vaccinated

A national survey has found that at the start of the COVID-19 vaccine rollout, most Canadians planned to get vaccinated, but that intentions were lower among certain demographic groups, including residents of Alberta, Manitoba and Saskatchewan, individuals without a university degree, and racialized Canadians.

2021-09-01T13:29:51-04:00August 31, 2021|General vaccine surveillance, Media Releases|

Tracking health events after vaccination: latest results from CANVAS-COVID

Are you among the over 1 million Canadians asked to complete a survey after receiving the first or second dose of a COVID-19 vaccine? The CANVAS-COVID study, funded by the CITF/VSRG, has been collecting self-reported information on health events following vaccination. The most common health event following vaccination, experienced by 52% of participants enrolled, [...]

2021-08-03T10:23:44-04:00August 3, 2021|General vaccine surveillance|

Vaccine effectiveness against the Gamma variant in a long-term care home in Ontario

An Ontario long-term care home (LTC) suffered a SARS-CoV-2 outbreak attributed to the Gamma variant. Researchers from a CITF-funded study led by Dr. Allison McGeer have published results in Clinical Infectious Diseases revealing that among the residents and staff considered to be part of the outbreak, 77% and 45% respectively, were fully vaccinated. The [...]

2021-07-19T16:24:06-04:00July 20, 2021|General vaccine surveillance|

Effectiveness of COVID-19 vaccines against VOCs in Canada

The race to vaccinate the world became more urgent with the emergence of variants of concern (VOCs). In a recent pre-print, not yet peer-reviewed, researchers from the Canadian Immunization Research Network (CIRN), including CITF-funded researchers Dr. Deshayne Fell, Dr. Jeff Kwong and Dr. Kumanan Wilson, estimated the effectiveness of vaccines given between December 2020 [...]

2021-07-13T10:25:46-04:00July 13, 2021|General vaccine surveillance|

mRNA COVID-19 vaccines are shown to be highly effective after two doses against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes

Researchers from the Canadian Immunization Research Network (CIRN) assessed the effectiveness of mRNA vaccines against symptomatic COVID-19 infection and severe outcomes and showed promising results. Researchers suggest that while one dose of the mRNA vaccine provides some protection that improves over time, two doses appear to be highly effective against severe outcomes. Their study [...]

2021-08-31T10:55:58-04:00June 8, 2021|General vaccine surveillance|

New Canada-Wide Research to Study Mixing-and-Matching COVID-19 vaccines

The Government of Canada, through the COVID-19 Immunity Task Force (CITF) and the Vaccine Surveillance Reference Group (VSRG), is supporting a new nation-wide study that will look at the effects of ‘mixing-and-matching’ approved COVID-19 vaccines in adults. Approximately $4.8 million is being provided for this study, which will assess the safety and effectiveness of using two different COVID-19 vaccines for the first and second dose. The project will also study the effects of increasing the interval between doses.

Go to Top